|
gptkbp:instanceOf
|
gptkb:antiviral_drug
gptkb:antineoplastic_agent
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:India
gptkb:Mexico
gptkb:United_States
|
|
gptkbp:ATCCode
|
gptkb:P01AX11
|
|
gptkbp:bioavailability
|
gptkb:unknown
|
|
gptkbp:brand
|
Alinia
Daxon
Kidonax
Nitazox
|
|
gptkbp:CASNumber
|
55981-09-4
|
|
gptkbp:category
|
gptkb:nitro_compound
antiviral
antiparasitic
antiprotozoal
thiazole
|
|
gptkbp:chemicalFormula
|
C12H9N3O5S
|
|
gptkbp:contraindication
|
severe renal impairment
severe hepatic impairment
hypersensitivity to nitazoxanide
|
|
gptkbp:developedBy
|
Romark Laboratories
|
|
gptkbp:discoveredBy
|
Jean-François Rossignol
|
|
gptkbp:eliminationHalfLife
|
1.1 hours (tizoxanide)
|
|
gptkbp:excretion
|
urine
bile
feces
|
|
gptkbp:firstDescribed
|
1984
|
|
gptkbp:IUPACName
|
2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits pyruvate:ferredoxin oxidoreductase enzyme-dependent electron transfer
|
|
gptkbp:metabolism
|
tizoxanide
|
|
gptkbp:molecularWeight
|
307.28 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
>99%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
abdominal pain
headache
|
|
gptkbp:usedFor
|
treatment of giardiasis
treatment of amoebiasis
treatment of cryptosporidiosis
treatment of viral gastroenteritis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Cryptosporidium
gptkb:Giardia
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nitazoxanide
|